PD-1: PD-L1 [Biotinylated] Inhibitor Screening ELISA Kit | EP-130-96tests

PD-1: PD-L1 [Biotinylated] Inhibitor Screening ELISA Kit | EP-130| Gentaur Distribution US, UK & Europe

Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.

Source: Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.

Molecule: PDN/A1.

Format: Solid.

Species: Human.

Application: The inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors.

Kit Component: This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human PD-L1 to immobilized human PD-1 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated PD-L1 protein, a human PD-1 protein, an anti-PD-1 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

Stability: The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.

Storage Conditions: 2-8℃.

Shipping Conditions: RT